



Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2006

January 30, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2006--Alkermes, Inc. (Nasdaq: ALKS) will host a conference call at 4:30 p.m. EST on Tuesday, February 7, 2006 to discuss the Company's financial results for its third quarter of fiscal 2006. Management will review the quarter and provide an update on the Company.

The conference call may be accessed by dialing 1-866-244-4517 for domestic callers and 1-703-639-1169 for international callers. The conference call ID number is 846330. Additionally, the call will be webcast on the investor relations section of Alkermes' website at www.alkermes.com and archived on the site until Monday, February 13, 2006 at 5:00 p.m. EST.

A replay of the conference call will be available from 7:30 p.m. EST on February 7, 2006 through 5:00 p.m. EST on February 13, 2006, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 846330.

Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, RISPERSDAL(R) CONSTA(R) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson. The Company's lead proprietary product candidate, VIVITROL(TM) (naltrexone for extended-release injectable suspension), is being developed as a once-monthly injection for the treatment of alcohol dependence. The Company has a pipeline of extended-release injectable products and pulmonary drug products based on its proprietary technology and expertise. Alkermes' product development strategy is twofold: the Company partners its proprietary technology systems and drug delivery expertise with several of the world's finest pharmaceutical companies and it also develops novel, proprietary drug candidates for its own account. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Alkermes, Inc.
Debra Koufos, 617-583-6220
Associate, Corporate Communications

SOURCE: Alkermes, Inc.